These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28359792)

  • 41. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
    Hoyt SB; Taylor J; London C; Ali A; Ujjainwalla F; Tata J; Struthers M; Cully D; Wisniewski T; Ren N; Bopp C; Sok A; Verras A; McMasters D; Chen Q; Tung E; Tang W; Salituro G; Clemas J; Zhou G; MacNeil D; Duffy R; Xiong Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2384-2388. PubMed ID: 28416132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
    Peter M; Dubuis JM; Sippell WG
    Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells.
    Ye P; Nakamura Y; Lalli E; Rainey WE
    Endocrinology; 2009 Mar; 150(3):1303-9. PubMed ID: 18974272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: design, synthesis, and biological evaluation.
    Ali A; Taylor GE; Ellsworth K; Harris G; Painter R; Silver LL; Young K
    J Med Chem; 2003 May; 46(10):1824-30. PubMed ID: 12723946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
    Liu Y; Wu J; Zhou M; Chen W; Li D; Wang Z; Hornsperger B; Aebi JD; Märki HP; Kuhn B; Wang L; Kuglstatter A; Benz J; Müller S; Hochstrasser R; Ottaviani G; Xin J; Kirchner S; Mohr S; Verry P; Riboulet W; Shen HC; Mayweg AV; Amrein K; Tan X
    J Med Chem; 2020 Jul; 63(13):6876-6897. PubMed ID: 32530624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin.
    Takeda Y; Miyamori I; Yoneda T; Hatakeyama H; Inaba S; Furukawa K; Mabuchi H; Takeda R
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2797-800. PubMed ID: 8768832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
    Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
    J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2).
    Martin RE; Lehmann J; Alzieu T; Lenz M; Carnero Corrales MA; Aebi JD; Märki HP; Kuhn B; Amrein K; Mayweg AV; Britton R
    Org Biomol Chem; 2016 Jul; 14(25):5922-7. PubMed ID: 27245438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
    Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
    J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart.
    Ye P; Kenyon CJ; MacKenzie SM; Jong AS; Miller C; Gray GA; Wallace A; Ryding AS; Mullins JJ; McBride MW; Graham D; Fraser R; Connell JM; Davies E
    Endocrinology; 2005 Dec; 146(12):5287-93. PubMed ID: 16179417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
    Gangjee A; Qiu Y; Li W; Kisliuk RL
    J Med Chem; 2008 Sep; 51(18):5789-97. PubMed ID: 18800768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
    Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.
    Peat AJ; Boucheron JA; Dickerson SH; Garrido D; Mills W; Peckham J; Preugschat F; Smalley T; Schweiker SL; Wilson JR; Wang TY; Zhou HQ; Thomson SA
    Bioorg Med Chem Lett; 2004 May; 14(9):2121-5. PubMed ID: 15080992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism.
    Takeda Y; Furukawa K; Inaba S; Miyamori I; Mabuchi H
    J Clin Endocrinol Metab; 1999 May; 84(5):1633-7. PubMed ID: 10323392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data.
    Lenzini L; Zanotti G; Bonchio M; Rossi GP
    Pharmacol Res; 2021 Jan; 163():105332. PubMed ID: 33271294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry.
    Nanba K; Tsuiki M; Sawai K; Mukai K; Nishimoto K; Usui T; Tagami T; Okuno H; Yamamoto T; Shimatsu A; Katabami T; Okumura A; Kawa G; Tanabe A; Naruse M
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1567-74. PubMed ID: 23443813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase.
    Condon JC; Pezzi V; Drummond BM; Yin S; Rainey WE
    Endocrinology; 2002 Sep; 143(9):3651-7. PubMed ID: 12193581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Letter by Keidar and Gamliel-Lazarovich regarding article, "Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial".
    Keidar S; Gamliel-Lazarovich A
    Circulation; 2012 May; 125(18):e653; author reply e654. PubMed ID: 22566356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.